Kairos Pharma Receives FDA Approval of Investigational New Drug (IND) Application for Its Phase 1 Clinical Trial of KROS 201 for the Treatment of Glioblastoma; Announces New Patent for KROS 401

/PRNewswire/ -- Kairos Pharma, Ltd. ("Kairos"), a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer,...

Related Keywords

United States ,Los Angeles ,Tagrisso Astrazeneca ,Neil Bhowmick ,John Yu ,Ramachandran Murali ,Kairos Pharma ,Trademark Office ,Cedars Sinai Medical Center ,Kairos Pharma Ltd ,Development Dr ,Cedars Sinai Medical ,Chief Scientific Officer Neil Bhowmick ,United States Patent ,Td ,